Plain-English translation of NCT07502495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing a new medication called icovamenib for people with type 2 diabetes whose blood sugar remains above target despite already taking standard diabetes medications. Half of the participants will receive icovamenib daily for 12 weeks along with their regular diabetes medications, while the other half will receive a placebo (a pill with no active medicine). The trial will measure whether the medication helps lower blood sugar better than the current treatment alone.
Many people with type 2 diabetes struggle to reach their blood sugar targets even while taking one or more diabetes medications. This trial is exploring whether this new treatment can help people achieve better control when added to their existing medications.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either icovamenib or a placebo pill once daily for 12 weeks, in addition to your regular diabetes medications. You will continue your current medications throughout the study and attend regular visits to have your blood sugar checked and discuss any side effects. The total trial lasts approximately 56 weeks, with more frequent visits in the first 12 weeks and follow-up visits afterward to monitor your health and measure how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States